Sanofi has been at the forefront of influenza vaccine development for over 70 years, delivering more than 5 billion doses across 100+ countries and immunizing over 250 million people annually. With a robust global network of production sites spanning Canada, France, Mexico, the United States, Australia, and China, Sanofi continues to invest in cutting-edge R&D across egg-based, recombinant, and mRNA platforms — ensuring the world gets the right shot against flu